Medical Oncology最新文献

Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02684-7

Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, Sama Hesham Samir, Swastik Pandita, Fatima Saeed, Dina Elraggal, Hebatullah Abdulazeem, Anwaar Saeed

{"title":"Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.","authors":"Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, Sama Hesham Samir, Swastik Pandita, Fatima Saeed, Dina Elraggal, Hebatullah Abdulazeem, Anwaar Saeed","doi":"10.1007/s12032-025-02684-7","DOIUrl":"https://doi.org/10.1007/s12032-025-02684-7","url":null,"abstract":"Patients with colorectal cancer (CRC) who have KRAS mutations often see poor results with standard treatments, leaving them with fewer viable options. Over the past few years, new KRAS G12C inhibitors have emerged as a targeted approach for a specific subset of these mutations, though their effectiveness and safety in advanced CRC remain areas of ongoing research. In this systematic review, we identified nine clinical trials including a total of 668 patients, by searching PubMed, Web of Science, CENTRAL, and Embase through October 2024. When sotorasib was used alone, the objective response rate (ORR) ranged from 7.1 to 9.7%, with disease control (DC) rates of 73.8 to 82.3% and a median progression-free survival (PFS) spanning 4-5.6 months. Combining sotorasib with panitumumab, especially at higher doses, raised its ORR to 26.4%. Meanwhile, pairing adagrasib with cetuximab led to a 42% ORR and a median PFS of 6.9 months, surpassing the 19% ORR observed with adagrasib alone. Divarasib monotherapy produced a 36% ORR and an 85.5% DC rate, with a PFS of 5.6 months; in tandem with cetuximab, those numbers climbed to a 62.5% ORR and a PFS of 8.1 months. Common side effects across these trials included diarrhea, nausea, fatigue, and various skin reactions. Overall, KRAS G12C inhibitors appear to offer meaningful benefits for CRC patients, particularly when used alongside EGFR inhibitors like cetuximab or panitumumab. However, further large-scale, randomized trials are needed to refine dosing strategies and gain a clearer picture of both efficacy and potential risks.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"127"},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prevalence of post-therapy epilepsy in patients treated for high-grade glial tumors: a systematic review and meta-analysis.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02677-6

Marta Pereira Ferreira, Ruben Lopes Carvalho, Daniel Filipe Borges, Joana Isabel Soares, João Casalta-Lopes

{"title":"The prevalence of post-therapy epilepsy in patients treated for high-grade glial tumors: a systematic review and meta-analysis.","authors":"Marta Pereira Ferreira, Ruben Lopes Carvalho, Daniel Filipe Borges, Joana Isabel Soares, João Casalta-Lopes","doi":"10.1007/s12032-025-02677-6","DOIUrl":"https://doi.org/10.1007/s12032-025-02677-6","url":null,"abstract":"Gliomas are the most prevalent type of primary brain tumor of the adult central nervous system. High-grade gliomas (HGG) are the most common type of glioma. Epilepsy is often the first clinical manifestation of HGG. Since epilepsy leads to increased morbidity and mortality rates, seizure control is one of the main therapeutic goals for patients with glioma-related epilepsy. Post-therapy epilepsy is observed in a significant percentage of patients, hence, this work aimed to quantify the prevalence of post-therapy epilepsy after HGG treatment. Our search was conducted across PubMed®, EMBASE®, Web of Science™, Cochrane Library, Sicelo and Scopus, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This review included articles published in Portuguese or English that evaluate adult patients with newly diagnosed HGG, who were treated with at least surgery or radiation. Thirty-six studies reporting on 4036 HGG patients were included in our meta-analysis. The mean age ranged from 44 to 73 years. Glioblastoma was the most commonly observed HGG, representing 77,8% of all glioma patients. The pre-treatment seizure frequency was observed in 21,2%. All patients underwent surgery as the main therapy, and 1842 patients received standard adjuvant therapy. We also observed a pooled prevalence of post-therapy seizures of 25.5% (95% confidence interval of [19.9%; 31.1%]). Substantial heterogeneity in all assessed variables was observed. Conducting larger prospective studies with suitable epilepsy diagnostic methods would help provide a more precise estimate of the number of HGG patients who develop post-therapy epilepsy.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"128"},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Urinary extracellular vesicle‑derived miR‑126‑3p predicts lymph node invasion in patients with high‑risk prostate cancer.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02636-1

Liang Dong, Cong Hu, Zehua Ma, Yiyao Huang, Greg Shelley, Morgan D Kuczler, Chi-Ju Kim, Kenneth W Witwer, Evan T Keller, Sarah R Amend, Wei Xue, Kenneth J Pienta

引用次数: 0

Correction to: The role of histamine and its receptors in breast cancer: from pathology to therapeutic targets.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02672-x

Hossein Azimi, Afifeh Jafari, Mahafarin Maralani, Homa Davoodi

引用次数: 0

Integrative analysis of ubiquitination-related genes identifies HSPA1A as a critical regulator in colorectal cancer progression.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-20 DOI: 10.1007/s12032-025-02662-z

Xinji Gao, Ting Yan, Xiang Yu, Qiang Li, Lan Zhao, QingShui Wang, Jun Wang

{"title":"Integrative analysis of ubiquitination-related genes identifies HSPA1A as a critical regulator in colorectal cancer progression.","authors":"Xinji Gao, Ting Yan, Xiang Yu, Qiang Li, Lan Zhao, QingShui Wang, Jun Wang","doi":"10.1007/s12032-025-02662-z","DOIUrl":"10.1007/s12032-025-02662-z","url":null,"abstract":"Colorectal cancer (CRC) is a prevalent and lethal malignancy, with ubiquitination significantly influencing cellular processes involved in cancer progression. However, the contributions of ubiquitination-related genes in CRC remain unclear. This study conducted a detailed analysis of gene expression profiles associated with ubiquitination in CRC, evaluating 1006 genes across 46 pathways. By comparing CRC tissues to adjacent normal tissues, we identified differentially expressed genes and developed a ubiquitination-related pathway gene signature (URPGS) using LASSO regression analysis on genes with prognostic significance. The prognostic capability of the URPGS was validated in independent cohorts, and its associations with clinical characteristics, including post-chemotherapy survival outcomes, were examined. Machine learning techniques identified HSPA1A as a key gene relevant to CRC both in vitro and in vivo. Our analysis revealed 307 differentially expressed ubiquitination-related genes, with 24 significantly associated with patient prognosis. The developed 14-gene URPGS exhibited strong prognostic value, effectively stratifying patients into high-risk and low-risk groups for overall survival. The URPGS correlated with advanced clinical stages, lymph node metastasis, and recurrence, with higher scores linked to poorer post-chemotherapy survival outcomes. Knockdown of HSPA1A significantly inhibited CRC cell proliferation, migration, and invasion in vitro, as well as tumor growth and metastasis in vivo. This research establishes a novel URPGS that effectively predicts prognosis and chemotherapy outcomes in CRC, enhancing our understanding of ubiquitination's role and suggesting personalized treatment strategies.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"123"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-20 DOI: 10.1007/s12032-025-02645-0

Xiao-Yu Zhang, Chan-Yuan Zhao, Jia-Ming Dong, Cun-Pu Du, Chen-Li Zhang, Ai-Jun Yang, Quan Zhou, Wei Liu, Yun Dang, Li-Na Shang, Yong-Ning Zhou, Yu-Ping Wang, Chen-Yu Wang, Min Wang, Min Li

{"title":"ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway.","authors":"Xiao-Yu Zhang, Chan-Yuan Zhao, Jia-Ming Dong, Cun-Pu Du, Chen-Li Zhang, Ai-Jun Yang, Quan Zhou, Wei Liu, Yun Dang, Li-Na Shang, Yong-Ning Zhou, Yu-Ping Wang, Chen-Yu Wang, Min Wang, Min Li","doi":"10.1007/s12032-025-02645-0","DOIUrl":"https://doi.org/10.1007/s12032-025-02645-0","url":null,"abstract":"Gastric cancer is one of the most common malignant tumors in the world. The occurrence of chemotherapy resistance seriously affects the survival and prognosis of middle and advanced patients. Enhancing DNA repair ability is one of the important mechanisms of chemotherapy resistance. ADAM9, a member of the disintegrin and metalloproteinase family, is involved in many biological processes, such as tumor cells proliferation, apoptosis, invasion and migration, vascular invasion, and drug resistance. In this study, we found that the high expression of ADAM9 in gastric cancer tissues was associated with a variety of clinicopathological factors and poor prognosis in patients. Gastric cancer cells with high ADAM9 expression reduced sensitivity to Cisplatin, decreased DNA damage, increased expression of ATM and CHK2, the key proteins in DNA damage repair pathway, and improved cancer cells survival rate. Further studies showed that the expression of ADAM9 was selectively interfered with gastric cancer cells, the expression levels of ATM and CHK2 were decreased, while the expression of damage protein γ-H2AX was significantly increased, the degree of DNA damage was increased, and the sensitivity of gastric cancer cells to Cisplatin was significantly enhanced. It is suggested that ADAM9 is involved in Cisplatin resistance in gastric cancer cells, and its mechanism is related to the activation of ATM-CHK2 pathway in DNA damage repair. These data demonstrate that ADAM9 plays a pro-cancer role and mediates Cisplatin resistance in gastric cancer, which may be a new target to overcome chemotherapy resistance.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"122"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An investigative study on the impact of DLK1 and NCoR1 knockdown by siRNA transfection on endometrial cancer proliferation: unveiling notch interactions.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-20 DOI: 10.1007/s12032-025-02676-7

Swathi Chandran Manimegalai, Sathiya Priya Krishnamoorthy, Vignesh Kalimuthu, Ramani Devi Thirunavukarasu, Sureka Chandrabose, Kadalmani Balamuthu

{"title":"An investigative study on the impact of DLK1 and NCoR1 knockdown by siRNA transfection on endometrial cancer proliferation: unveiling notch interactions.","authors":"Swathi Chandran Manimegalai, Sathiya Priya Krishnamoorthy, Vignesh Kalimuthu, Ramani Devi Thirunavukarasu, Sureka Chandrabose, Kadalmani Balamuthu","doi":"10.1007/s12032-025-02676-7","DOIUrl":"https://doi.org/10.1007/s12032-025-02676-7","url":null,"abstract":"Endometrial cancer is the most common gynecological malignancy. Despite advances in treatment, many patients experience disease recurrence or metastasis. This study investigates the impact of siRNA-mediated gene knockdown of NCoR1 and DLK1 genes in the proliferation of endometrial cancer cell lines Ishikawa and AN3CA and normal HEK 293 cells. Cellular growth and survival before and after the treatment of predesigned siRNAs in the endometrial cancer cell lines were evidenced using fluorescent stains. The mRNA expression of BID, BAX, BCL2, Caspases 3, 8, and 9 GPR78, EGFR, VEGF, NCoR1, DLK1 and ARID1A was analyzed in the untreated HEK 293, Ishikawa, and AN3CA cell lines to substantiate the oncogenic property of Ishikawa and AN3CA cell lines. Then, to evidence the successful transfection of NCoR1 and DLK1 gene in endometrial cancer cells, the mRNA and protein expression of targeted genes before and after being transfected were also validated. As a result, the mRNA expression significantly increased in BID, BAX, BCL2, GPR78, EGFR and VEGF. On the other hand, Caspases 3, 8, and 9 were down-regulated in Ishikawa and AN3CA compared to the control cell line (HEK 293). The mRNA and protein expression of NCoR1 and DLK1 in siRNA-mediated transfection supported the reduced proliferation in endometrial cancer cells by interfering with certain pathways like Notch, MAPK, SWI/SNF, and NF-κB, which have crucial roles in the grade of receptor to the histone remodeling. With these findings, the study recommends exploring the possible role and interactions of NCoR1 and DLK1, signaling pathways that favor the progression of endometrial cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"124"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pan-cancer analysis unveils the role and mechanisms of neddylation modifications in tumorigenesis.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-19 DOI: 10.1007/s12032-025-02658-9

Qianhua Hu, Xiang Li, Ping Wang, Ying Xie

{"title":"Pan-cancer analysis unveils the role and mechanisms of neddylation modifications in tumorigenesis.","authors":"Qianhua Hu, Xiang Li, Ping Wang, Ying Xie","doi":"10.1007/s12032-025-02658-9","DOIUrl":"https://doi.org/10.1007/s12032-025-02658-9","url":null,"abstract":"This study explores the roles of ubiquitin-like modification genes in pan-cancer, focusing on their regulatory mechanisms, prognostic implications, and drug sensitivity. Data on five key neddylation pathway genes (RBX1, NEDD8, NAE1, UBA3, UBE2M) were collected from TCGA and GTEx databases, covering mRNA expression, DNA methylation, SNVs, and CNVs. Gene expression differences between normal and cancer tissues, along with associations with genetic alterations, methylation, and cancer-related pathways, were analyzed. Drug sensitivity correlations were assessed using GDSC and CTRP databases. Neddylation pathway genes exhibit hypomethylation and overexpression across various cancers, correlating with poor prognosis. SNVs are predominantly missense mutations, while CNVs are mostly heterozygous deletions and amplifications. These genes regulate several key cancer-related pathways, such as DNA damage repair, cell cycle modulation, and inhibition of RTK/RAS/MAPK pathways. Ubiquitin-like modification genes are associated with poor prognosis due to their low methylation and high expression in cancers. Their genetic alterations impact cancer pathways, underscoring their potential as therapeutic targets and prognostic biomarkers.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"119"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addition of thalidomide for prevention of chemotherapy-induced nausea and vomiting in the second cycle after the failure of four-drug regimen in the first cycle.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-19 DOI: 10.1007/s12032-025-02655-y

Nishil Gowda, Mirunalini Ravichandran, Jeyaselvi Indrajithu, Tamizharasan Paninathan, Biswajit Dubashi, Smita Kayal, Prasanth Ganesan

{"title":"Addition of thalidomide for prevention of chemotherapy-induced nausea and vomiting in the second cycle after the failure of four-drug regimen in the first cycle.","authors":"Nishil Gowda, Mirunalini Ravichandran, Jeyaselvi Indrajithu, Tamizharasan Paninathan, Biswajit Dubashi, Smita Kayal, Prasanth Ganesan","doi":"10.1007/s12032-025-02655-y","DOIUrl":"https://doi.org/10.1007/s12032-025-02655-y","url":null,"abstract":"Four-drug antiemetic prophylaxis achieves emesis control in 70-90% of patients receiving highly emetogenic chemotherapy (HEC). However, less than half achieve control of nausea. We added thalidomide to OAOD (ondansetron, aprepitant, dexamethasone, and olanzapine) to try and improve nausea control. Adults (> 18 years) who had failed (\"any nausea\" in 0-120 h after HEC) OAOD prophylaxis in cycle 1, were randomly assigned to thalidomide (T = 50 mg OD for 5 days) + OAOD or placebo (P) + OAOD in cycle 2. The primary endpoint was the proportion of patients achieving \"no nausea\" in 0-120 h from chemotherapy in the second cycle. A sample size of 50 (including dropouts) would be able to detect 30% \"no nausea\" in the T arm (β = 80%, α = 0.05). We enrolled 105 patients in cycle 1 and randomized 49 patients (25 thalidomide/ 24 placebo; median age 45(30-60) years; all anthracycline/ cyclophosphamide for breast cancer). The addition of thalidomide did not improve the proportion with \"no nausea\" in the overall (0-120 h) [T (16%) vs. P (21%); p = 0.72)], acute (0-24 h) (32% vs. 25%, p = 0.58), and delayed (24-72 h) (32% vs. 25%, p = 0.46) periods. Severe nausea (VAS ≥ 7) in the delayed period was reduced (T = 4% vs. P = 30%, p = 0.02). Sedation and dizziness were not increased, but mild constipation was higher with thalidomide [T (84%) vs. P (58%), p = 0.047)]. The addition of thalidomide to standard 4-drug CINV prophylaxis in cycle 2 did not improve nausea control among patients who \"failed\" the 4-drug regimen in cycle 1.Trial Registration: The trial was registered ( www.ctri.nic.in ; CTRI/2021/08/035980).","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"121"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isoliquiritigenin attenuates tumor progression and PD-L1 expression by inhibiting the phosphorylation of STAT3 in melanoma.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-19 DOI: 10.1007/s12032-025-02666-9

Haiyan Zeng, Aoxiang Guo, Zhenyang Liu, Shijian Xiang, Fanghao Zheng

引用次数: 0